

# Stefano Menzo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4514304/publications.pdf>

Version: 2024-02-01

58  
papers

2,383  
citations

279798

23  
h-index

214800

47  
g-index

61  
all docs

61  
docs citations

61  
times ranked

2585  
citing authors

#	ARTICLE	IF	CITATIONS
1	Studies in Subjects with Long-Term Nonprogressive Human Immunodeficiency Virus Infection. <i>New England Journal of Medicine</i> , 1995, 332, 209-216.	27.0	717
2	A novel procedure for quantitative polymerase chain reaction by coamplification of competitive templates. <i>Gene</i> , 1992, 122, 313-320.	2.2	260
3	Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). <i>Aids</i> , 2006, 20, 795-803.	2.2	139
4	A human binding site for transcription factor USF/MLTF mimics the negative regulatory element of human immunodeficiency virus type 1. <i>Virology</i> , 1992, 186, 133-147.	2.4	94
5	Genotype and Phenotype Patterns of Human Immunodeficiency Virus Type 1 Resistance to Enfuvirtide during Long-Term Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 3253-3259.	3.2	83
6	Trans-Activation of Epidermal Growth Factor Receptor Gene by the Hepatitis B Virus X-Gene Product. <i>Virology</i> , 1993, 196, 878-882.	2.4	68
7	Insulin-like growth factor 1 expression correlates with clinical outcome in KRAS wild type colorectal cancer patients treated with cetuximab and irinotecan. <i>International Journal of Cancer</i> , 2010, 127, 1941-1947.	5.1	67
8	Distribution and molecular analysis of mef(A)-containing elements in tetracycline-susceptible and -resistant <i>Streptococcus pyogenes</i> clinical isolates with efflux-mediated erythromycin resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 54, 991-998.	3.0	57
9	Detection of human immunodeficiency virus type 1 genomic RNA in plasma samples by reverse-transcription polymerase chain reaction. <i>Journal of Medical Virology</i> , 1991, 34, 89-95.	5.0	49
10	Absence of Neuroinvasive Disease in a Liver Transplant Recipient Who Acquired West Nile Virus (WNV) Infection from the Organ Donor and Who Received WNV Antibodies Prophylactically. <i>Clinical Infectious Diseases</i> , 2010, 51, e34-e37.	5.8	47
11	Molecular Tracing of SARS-CoV-2 in Italy in the First Three Months of the Epidemic. <i>Viruses</i> , 2020, 12, 798.	3.3	46
12	Clinicopathological features of primary cutaneous B-cell lymphomas from an academic regional hospital in central Italy: No evidence of <i>Borrelia burgdorferi</i> association. <i>Leukemia and Lymphoma</i> , 2007, 48, 2184-2188.	1.3	40
13	Competitive polymerase chain reaction for quantitating feline immunodeficiency virus load in infected cat tissues. <i>Molecular and Cellular Probes</i> , 1994, 8, 229-234.	2.1	38
14	Circulating SARS-CoV-2 variants in Italy, October 2020–March 2021. <i>Virology Journal</i> , 2021, 18, 168.	3.4	36
15	Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 616-624.	3.0	34
16	Host-Specific Modulation of the Selective Constraints Driving Human Immunodeficiency Virus Type 1 <i>env</i> Gene Evolution. <i>Journal of Virology</i> , 1999, 73, 3764-3777.	3.4	34
17	Processivity and drug-dependence of HIV-1 protease. <i>Aids</i> , 2003, 17, 663-671.	2.2	31
18	Sequence analysis of the hepatitis B virus pre-C region in hepatocellular carcinoma [HCC] and nontumoral liver tissues from HCC patients. <i>Virology</i> , 1992, 188, 890-895.	2.4	29

#	ARTICLE	IF	CITATIONS
19	Rare mutations in a domain crucial for V3-loop structure prevail in replicating HIV from long-term non-progressors. <i>Aids</i> , 1998, 12, 985-997.	2.2	27
20	Evaluation of the Ion AmpliSeq SARS-CoV-2 Research Panel by Massive Parallel Sequencing. <i>Genes</i> , 2020, 11, 929.	2.4	27
21	Frequency and Treatment-Related Predictors of Thymidine Analogue Mutation Patterns in HIV-1 Isolates after Unsuccessful Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2006, 193, 1219-1222.	4.0	26
22	First Detection of SARS-CoV-2 by Real-Time Reverse Transcriptase-Polymerase Chain Reaction Assay in Pleural Fluid. <i>Chest</i> , 2020, 158, e143-e146.	0.8	26
23	A single-step DNA extraction procedure for the detection of serum hepatitis B virus sequences by the polymerase chain reaction. <i>Journal of Virological Methods</i> , 1991, 32, 245-253.	2.1	25
24	Detection of human immunodeficiency virus type 1 transcripts in peripheral blood lymphocytes by the polymerase chain reaction. <i>Journal of Virological Methods</i> , 1991, 32, 31-39.	2.1	24
25	Competitive polymerase chain reaction and analysis of viral activity at the molecular level. <i>Genetic Analysis, Techniques and Applications</i> , 1994, 11, 1-6.	1.5	24
26	Identification of Six Putative Novel Human Papillomaviruses (HPV) and Characterization of Candidate HPV Type 87. <i>Journal of Virology</i> , 2001, 75, 11913-11919.	3.4	22
27	Visceral fat inflammation and fat embolism are associated with lung's lipidic hyaline membranes in subjects with COVID-19. <i>International Journal of Obesity</i> , 2022, 46, 1009-1017.	3.4	22
28	Clearance of HIV-1 viraemia after seroconversion. <i>Lancet, The</i> , 1993, 341, 315-316.	18.7	21
29	Molecular epidemiology and pathogenic potential of underdiagnosed human papillomavirus types. <i>BMC Microbiology</i> , 2008, 8, 112.	3.3	21
30	Inhibition of R5X4 Dualtropic HIV-1 Primary Isolates by Single Chemokine Co-receptor Ligands. <i>Virology</i> , 2001, 280, 253-261.	2.4	19
31	Evolutionary pattern of pandemic influenza (H1N1) 2009 virus in the late phases of the 2009 pandemic.. <i>PLOS Currents</i> , 2010, 2, RRN1149.	1.4	18
32	HIV-1 replication capacity and genotype changes in patients undergoing treatment interruption or lamivudine monotherapy. <i>Journal of Medical Virology</i> , 2008, 80, 201-208.	5.0	17
33	Analysis of the functional relationship between V3 loop and gp120 context with regard to human immunodeficiency virus coreceptor usage using naturally selected sequences and different viral backbones. <i>Virology</i> , 2003, 307, 328-340.	2.4	16
34	Genotypic and Phenotypic Correlates of the HIV Type 1 env Gene Evolution in Infected Children with Discordant Response to Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 1306-1313.	1.1	14
35	Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy. <i>Antiviral Therapy</i> , 2009, 14, 359-369.	1.0	14
36	Quantitative evaluation of the recombinant HIV-1 phenotype to protease inhibitors by a single-step strategy. <i>Aids</i> , 2000, 14, 1101-1110.	2.2	13

#	ARTICLE	IF	CITATIONS
37	Molecular and cellular determinants of cell-to-cell transmission of HCV in vitro. <i>Journal of Medical Virology</i> , 2007, 79, 1491-1499.	5.0	12
38	Hepatitis E in a region of Italy: An emerging autochthonous infection?. <i>Digestive and Liver Disease</i> , 2016, 48, 1340-1345.	0.9	11
39	Comparison of levels of HIV-1 resistance to protease inhibitors by recombinant versus conventional virus phenotypic assay and two genotypic interpretation procedures in treatment-naïve and HAART-experienced HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 135-139.	3.0	10
40	Lack of detectable human T-cell lymphotropic virus type I sequences in samples from multiple sclerosis patients. <i>Journal of Medical Virology</i> , 1992, 36, 155-161.	5.0	9
41	Slow response to entecavir treatment in treatment-naïve HBV patients is conditioned by immune response rather than by the presence or selection of refractory variants. <i>Antiviral Therapy</i> , 2013, 19, 201-209.	1.0	9
42	Processivity and drug-dependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitors. <i>Aids</i> , 2003, 17, 663-71.	2.2	9
43	Low Abundance Drug Resistance Mutations: Extending the HIV Paradigm to Hepatitis B Virus. <i>Journal of Infectious Diseases</i> , 2009, 200, 1798-1799.	4.0	8
44	Hemagglutinin 222 Variants in Pandemic (H1N1) 2009 Virus. <i>Emerging Infectious Diseases</i> , 2011, 17, 749-751.	4.3	8
45	Surgery and topic cidofovir for nasal squamous papillomatosis in HIV+ patient. <i>European Archives of Oto-Rhino-Laryngology</i> , 2009, 266, 937-939.	1.6	7
46	Long-Term Follow-Up of Acute Hepatitis B: New Insights in Its Natural History and Implications for Antiviral Treatment. <i>Genes</i> , 2018, 9, 293.	2.4	7
47	Evolutionary trends of resistance mutational patterns of HBV reverse transcriptase over years (2002-2012) of different treatment regimens: The legacy of lamivudine/adefovir combination treatment. <i>Antiviral Research</i> , 2017, 143, 62-68.	4.1	6
48	Human papillomavirus infections: new perspectives for prevention and treatment. <i>New Microbiologica</i> , 2007, 30, 189-212.	0.1	6
49	Phylogeography and genomic epidemiology of SARS-CoV-2 in Italy and Europe with newly characterized Italian genomes between February-June 2020. <i>Scientific Reports</i> , 2022, 12, 5736.	3.3	6
50	Trend of clinical vancomycin-resistant enterococci isolated in a regional Italian hospital from 2001 to 2018. <i>Brazilian Journal of Microbiology</i> , 2020, 51, 1607-1613.	2.0	5
51	Locally acquired hepatitis E virus in Marche Italy: Clinical/laboratory features and outcome. <i>Digestive and Liver Disease</i> , 2020, 52, 434-439.	0.9	4
52	Antimicrobial Resistance: A Challenge for the Future. , 2020, , 13-29.		3
53	Simple and Reliable Method to Quantify the Hepatitis B Viral Load and Replicative Capacity in Liver Tissue and Blood Leukocytes. <i>Hepatitis Monthly</i> , 2016, 16, e28751.	0.2	3
54	Weak Cross-Lineage Neutralization by Anti SARS-CoV-2 Spike Antibodies after Natural Infection or Vaccination Is Rescued by Repeated Immunological Stimulation. <i>Vaccines</i> , 2021, 9, 1124.	4.4	3

#	ARTICLE	IF	CITATIONS
55	Determinants of HIV-1 Genotypic Resistance to Darunavir (TMC114) in a Large Italian Resistance Database (Antiretroviral Resistance Cohort Analysis). <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2007, 46, 373-375.	2.1	1
56	<i>No pol</i> mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy. <i>Journal of Medical Virology</i> , 2011, 83, 391-398.	5.0	1
57	Quantification of the HIV-1 total reservoir in the peripheral blood of naïve and treated patients by a standardised method derived from a commercial HIV-1 RNA quantification assay. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 609-617.	2.3	1
58	A Large Epidemic of Hepatitis B in Serbia: An Integrated Model for Outbreak Investigations in Healthcare Settings. <i>Infection Control and Hospital Epidemiology</i> , 2014, 35, 732-735.	1.8	1